Nivolumab incuded colitis in a cancer patient: therapeutic dilemmas and patient-related factors
Intercontinental Journal of Internal Medicine · 28.02.2026 · 4 (1) · 26-27
DOI: 10.51271/icjim-0071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Intercontinental Journal of Internal Medicine, online erschienen am 28.02.2026. Verfasst von Cansın Taşkın und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Nivolumab is a current type of monoclonal IgG4 antibody used to treat many types of cancer, including stomach cancer, lymphoma, malignant melanoma and non-small cell lung cancer. Side effects associated with immune checkpoint inhibitors and tyrosine kinase inhibitors are increasingly recognized and presented as literature information. One of the most commonly affected systems is the gastrointestinal system. This case report presents a case of nivolumab-associated colitis in a patient with metastatic lung cancer, where treatment decisions were complicated by oncologic needs and patient compliance issues.
Zitieren
APA
Taşkın, C., & Tanoğlu, A. (2026). Nivolumab incuded colitis in a cancer patient: therapeutic dilemmas and patient-related factors. Intercontinental Journal of Internal Medicine, 4(1), 26-27. https://doi.org/10.51271/icjim-0071
Vancouver
Taşkın C, Tanoğlu A. Nivolumab incuded colitis in a cancer patient: therapeutic dilemmas and patient-related factors. Intercontinental Journal of Internal Medicine. 2026;4(1):26-27. doi:10.51271/icjim-0071
BibTeX
@article{Takn2026,
author = {Taşkın, Cansın and Tanoğlu, Alpaslan},
title = {Nivolumab incuded colitis in a cancer patient: therapeutic dilemmas and patient-related factors},
journal = {Intercontinental Journal of Internal Medicine},
year = {2026},
volume = {4},
number = {1},
pages = {26--27},
doi = {10.51271/icjim-0071}
}
EUVIMED